ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0854

Outcome of Uveitis in Juvenile Idiopathic Arthritis and Spondyloarthritis Patients – a 5-year Follow up Study

Filipe Pinheiro1, Mariana Leuzinger-Dias2, Bruno Fernandes3, Diogo Fonseca4, Joana Vilaça5, Luís Figueira6 and Iva Brito7, 1Rheumatology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, 2Ophtalmology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, 3Rheumatology Deparment, Centro Hospitalar e Universitário de São João, Porto, Portugal, 4Rheumatology Department, Centro Hospitalar de Vila Nova de Gaia / Espinho, Vila Nova de Gaia, Portugal, 5Paediatrics Department, Hospital de Braga, Braga, Portugal, 6Ophthalmology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, 7Pediatric and Young Adult Rheumatology Unit, Centro Hospitalar Universitário de São João, Porto, Portugal

Meeting: ACR Convergence 2022

Keywords: Eye Disorders, Juvenile idiopathic arthritis, Spondyloarthropathies

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Pediatric Rheumatology – Clinical Poster I: JIA

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Uveitis is a frequent complication of juvenile idiopathic arthritis (JIA) and juvenile spondyloarthritis (jSpA), and diagnosis is often challenging. The importance of uveitis relates to potential complications, and prognosis depends on early recognition and treatment. The aim of this study is to evaluate the prevalence and risk factors for complications associated with uveitis in patients with JIA and jSpA.

Methods: A longitudinal, monocentric cohort study that included patients diagnosed with JIA and jSpA, who developed uveitis. Demographic, laboratory, and clinical data were collected including complications of uveitis, HLA-B27, antinuclear antibodies, erythrocyte sedimentation rate, C-reactive protein, visual acuity and DMARD treatment. Follow-up was 5 years after uveitis’ diagnosis. Comparison between groups (complicated versus uncomplicated uveitis) was evaluated using chi-square, t test and Mann-Whitney test. Logistic regression was performed to determine predictors of complications.

Results: A total of 270 patients were evaluated, of which 37 patients (13.7%) had uveitis and were included in this study. Twenty patients were female (54.1%), age 11.9±8.7 years at diagnosis of jSpA/JIA and 15.3±9.9 years at diagnosis of uveitis. Twenty-seven patients (73.0%) had a diagnosis of JIA (23 with oligoarticular disease) and in 12 patients (32.4%) uveitis was the first manifestation of the rheumatic disease. Fifteen (40.5%) patients exhibited complications during follow-up period, namely cataract (n=11), synechiae and ocular hypertension (n=7), keratopathy (n=6), vitritis (n=3), retinal detachment (n=2), hemovitreous and glaucoma (n=1). Eleven patients (29.7%) underwent ophthalmologic surgery.

Comparisons between complicated versus uncomplicated uveitis patients showed that complications were significantly more frequent in those who had uveitis as the initial presentation (53.3% vs 18.2%, p=0.04), diagnosis of JIA (93.3% vs 59.1%, p=0.03), a younger age at diagnosis of uveitis (8.9 ± 5.7 vs 17.7 ± 10.1, p=0.01) and age at the diagnosis of rheumatic disease (5.4 ± 4.6 vs 14.3 ± 8.7, p=0.01); no significant differences were found between the groups in the other variables studied.

Univariate logistic regression analysis showed that JIA (OR 9.69, CI 1.07-87.44, p=0.04), presentation as uveitis (OR 5.14, CI 1.17-22.69, p=0.03), age at diagnosis of jSpA/JIA (OR 0.88, CI 0.79-0.98, p= 0.02) and age of uveitis (OR 0.90, CI 0.82-0.99, p=0.02) were predictors of complications. When adjusting for age of uveitis, age at diagnosis and JIA, uveitis as first manifestation of rheumatic disease was found to be an independent predictor of complications (OR 101.77, CI 3.08-3358.7, p=0.01)

Conclusion: Ophthalmologic complications of uveitis occur in a significant percentage of patients with JIA and jSpA. The initial presentation of rheumatic disease as uveitis is significantly associated with the occurrence of uveitis complications, so it is essential that there is a collaboration between ophthalmologist and rheumatologist in the diagnosis and treatment of these patients.


Disclosures: F. Pinheiro, None; M. Leuzinger-Dias, None; B. Fernandes, None; D. Fonseca, None; J. Vilaça, None; L. Figueira, None; I. Brito, None.

To cite this abstract in AMA style:

Pinheiro F, Leuzinger-Dias M, Fernandes B, Fonseca D, Vilaça J, Figueira L, Brito I. Outcome of Uveitis in Juvenile Idiopathic Arthritis and Spondyloarthritis Patients – a 5-year Follow up Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/outcome-of-uveitis-in-juvenile-idiopathic-arthritis-and-spondyloarthritis-patients-a-5-year-follow-up-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/outcome-of-uveitis-in-juvenile-idiopathic-arthritis-and-spondyloarthritis-patients-a-5-year-follow-up-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology